Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Hudzik TJ"'
Autor:
Hudzik TJ; ALA BioPharma Consulting, Monroe, NJ, USA., Huestis MA; Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA., Rossi SS; Department of Health Surveillance and Bioethics, Forensic Toxicology Laboratory, Università Cattolica del Sacro Cuore F. Policlinico Gemelli IRCCS, Rome, Italy., Schumacher YO; Aspetar Orthopaedic and Sports Medicine Hospital, Doha, Qatar., Harcourt P; Australian Football League, Docklands, VIC, Australia., Budgett R; Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland., Stuart M; International Testing Agency-ITA, Lausanne, Switzerland., Tettey J; United Nations Office on Drugs and Crime, Vienna International Centre, Vienna, Austria., Mazzoni I; Science and Medicine Department, World Anti-Doping Agency, Montreal, Quebec, Canada., Rabin O; Science and Medicine Department, World Anti-Doping Agency, Montreal, Quebec, Canada., Danion A; Science and Medicine Department, World Anti-Doping Agency, Montreal, Quebec, Canada., Culler M; Amolyt Pharma, Cambridge, MA, USA., Handelsman D; The ANZAC Research Institute Concord Repatriation General Hospital Gate 3, Concord, NSW, Australia., Thevis M; Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany., Kinahan A; Eirpharm, Ennis, County Clare, Ennis, Ireland.
Publikováno v:
Addiction (Abingdon, England) [Addiction] 2023 Nov; Vol. 118 (11), pp. 2040-2042. Date of Electronic Publication: 2023 Aug 13.
Autor:
Jones JD; Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA., Varshneya NB; Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, 410 N 12th St, Richmond, VA 23298, USA.; Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA., Hudzik TJ; In Vitro In Vivo Translation, NonClinical Safety, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426, USA., Huhn AS; Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.
Publikováno v:
Current addiction reports [Curr Addict Rep] 2021 Mar; Vol. 8 (1), pp. 109-121. Date of Electronic Publication: 2021 Jan 12.
Autor:
Hudzik TJ; Department of Research, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, PA, 1926, USA., Patel M; Department of Research, GlaxoSmithKline, Gunnels Wood Rd, Stevenage, SG1 2NY, UK., Brown A; Department of Research, GlaxoSmithKline, Gunnels Wood Rd, Stevenage, SG1 2NY, UK.
Publikováno v:
Drug testing and analysis [Drug Test Anal] 2021 Feb; Vol. 13 (2), pp. 261-267. Date of Electronic Publication: 2021 Jan 12.
Autor:
de Zafra CLZ; Comparative Biology and Safety Sciences, Amgen, Inc., South San Francisco, CA, USA. Electronic address: cdezafra@amgen.com., Markgraf CG; Preclinical Safety, Discovery Sciences Support, Merck & Co., Ltd., Kenilworth, NJ, USA., Compton DR; Preclinical Safety, Sanofi US, Bridgewater, NJ, USA., Hudzik TJ; ALA BioPharma Consulting, Chicago, IL, USA.
Publikováno v:
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2018 Feb; Vol. 92, pp. 165-172. Date of Electronic Publication: 2017 Dec 02.
Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behavior.
Autor:
Goody SMG; Pfizer Drug Safety Research & Development, Groton, CT, USA. Electronic address: susan.goody@pfizer.com., Cannon KE; Halozyme Inc, San Diego, CA, USA., Liu M; Drinker, Biddle and IQ Consortium, Washington, DC, USA., Kallman MJ; Kallman Preclinical Consulting, Greenfield, IN, USA., Martinolle JP; Sanofi Research & Development, Montpellier, France., Mazelin-Winum L; Sanofi Research & Development, Montpellier, France., Giarola A; GlaxoSmithKline Safety Pharmacology Department, Ware, UK., Ardayfio P; Eli Lilly and Company, Indianapolis, IN, USA., Moyer JA; Janssen Research & Development, Titusville, NJ, USA., Teuns G; Janssen Research & Development, Beerse, Belgium., Hudzik TJ; ALA BioPharm Consulting, Gurnee, IL, USA.
Publikováno v:
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2017 Oct; Vol. 89, pp. 288-301. Date of Electronic Publication: 2017 Jul 27.
Autor:
Hudzik TJ; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Preclinical Safety, Development Sciences, United States; ALA BioPharma Consulting, United States. Electronic address: tom.hudzik@alacgroup.com., Basso AM; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Discovery Translational Sciences, United States., Lynch JJ 3rd; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Discovery Safety Pharmacology, United States., Bracken WM; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Preclinical Safety, Development Sciences, United States., Mohler EG; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Discovery Neuroscience, United States., Kohlhaas KL; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Discovery Neuroscience, United States., Xu H; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Department of Bioanalysis, United States., Haig G; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Neuroscience Clinical Development, United States., Gault L; AbbVie Pharmaceutical Research and Development, 1 North Waukegan Rd, North Chicago, IL 60064, United States; Neuroscience Clinical Development, United States.
Publikováno v:
Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2017 Jul; Vol. 158, pp. 22-31. Date of Electronic Publication: 2017 Jun 01.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marek GJ; Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.) gerard.marek@astellas.com., Day M; Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.)., Hudzik TJ; Astellas Pharma Development, Northbrook, Illinois (G.J.M.); Alexion Pharmaceuticals, Cheshire, Connecticut (M.D.); and AbbVie, North Chicago. Illinois (T.J.H.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Mar; Vol. 356 (3), pp. 534-48. Date of Electronic Publication: 2015 Dec 23.
Autor:
Backes K; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Lorenz H; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Laplanche L; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Hudzik TJ; AbbVie Inc., Lake County, Illinois, USA., Potschka H; Institute of Pharmacology, Toxicology and Pharmacy, Ludwig-Maximilians-University (LMU), Munich, Germany., Hempel K; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Electronic address: katja.hempel@abbvie.com.
Publikováno v:
Toxicology letters [Toxicol Lett] 2016 Jan 22; Vol. 243, pp. 78-87. Date of Electronic Publication: 2015 Dec 28.
Autor:
Roberts RA; ApconiX, BioHub at Alderley Park, Cheshire SK10 4TG, UK; ruth.roberts@apconix.com., Aschner M; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461;, Calligaro D; Eli Lilly & Co., Pharmacology/Toxicology Research Lilly Research Labs, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285;, Guilarte TR; §Columbia University, New York, New York 10032;, Hanig JP; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland 20993;, Herr DW; US EPA, Toxicology Assessment Division, NHEERL, Research Triangle Park, North Carolona 27711;, Hudzik TJ; AbbVie, Inc., North Chicago, Illinois 60064;, Jeromin A; Quanterix, Inc., Lexington, Massachusetts 02421;, Kallman MJ; Covance, Inc., 8211 SciCor Drive, Indianapolis, Indiana 46214;, Liachenko S; *U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas 72079;, Lynch JJ 3rd; Quanterix, Inc., Lexington, Massachusetts 02421;, Miller DB; Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505; and., Moser VC; US EPA, Toxicology Assessment Division, NHEERL, Research Triangle Park, North Carolona 27711;, O'Callaghan JP; Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505; and., Slikker W Jr; *U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas 72079;, Paule MG; Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505; and.
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2015 Dec; Vol. 148 (2), pp. 332-40.